• Appointment will lead research strategy to apply the latest scientific innovations to Optibrium’s computational and AI drug discovery technologies
• Hamed brings extensive computational engineering and design experience from industry leader, Illumina

CAMBRIDGE, UK – Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the appointment of Dr Hamed Tabatabaei Ghomi as Head of Research. The latest in a series of senior-level hires, Hamed brings strategic and industrial research expertise in the chem- and bioinformatics space, backed by an impressive academic track record. As Director of Research, Hamed will lead Optibrium’s Research Team to develop and implement breakthrough methods, including quantum mechanical and machine learning approaches, to improve the productivity and efficiency of drug discovery.

Working alongside the Software Development and Business Development teams, Hamed will ensure the translation of Optibrium’s in-house R&D into valuable drug discovery tools and services, such as new metabolism modelling capabilities for the Company’s lead product, StarDrop, a comprehensive suite of drug discovery software.

Hamed joins Optibrium from Illumina, where he focused on computational protein engineering and small molecule design as Bioinformatics Manager. His industrial research experience is complemented by several academic degrees, including a PhD in the Philosophy of Science from the University of Cambridge and a PhD in Computational Drug Design from Purdue University. He completed his postdoctoral research in computational epigenetics and protein engineering at the University of California and has contributed to multiple scientific publications focused on advances in bioinformatics, medicinal chemistry, and computational biology. Starting his career as a Pharmacist at Exir Pharmaceutical Company, Hamed also has expertise in pharmacovigilance and regulation compliance.

Dr Hamed Tabatabaei Ghomi, Director of Research, Optibrium, said: “I am delighted to be joining Optibrium at such a dynamic and exciting stage of growth. Its world-class team sits at the forefront of machine learning and quantum mechanical modelling, and I look forward to translating the Company’s breakthrough R&D into impactful solutions for our customers’ drug discovery programmes.”

Dr Matthew Segall, Chief Executive Officer, Optibrium, said: “We are pleased to welcome Hamed to the team. His impressive depth of industry and academic experience, centred around computational chemistry and bioinformatics, will drive cutting-edge advances in Optibrium’s R&D, helping us to deliver the latest innovations in drug discovery to our users worldwide.”

For further information on Optibrium or StarDrop, please visit www.optibrium.com, contact [email protected] or call +44 1223 815900.

ENDS

Notes to Editors

 Media contact

Esmé Walters

Zyme Communications

Email: [email protected]

Optibrium

Michelle Harrison

Head of Strategic Marketing

Email: [email protected]

About Optibrium

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium’s lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company’s Augmented Chemistry® products and services, including Cerella™ deliver proven artificial intelligence technologies that continuously learn from all available data to supplement researchers’ experience and skills.

Optibrium was founded in 2009 and is headquartered in Cambridge, UK, with a US subsidiary, Optibrium Inc., based in Cambridge MA. The company works closely with over 180 customers and collaborators worldwide, including leading global pharma, biotech, agrochemical and flavouring companies and not-for-profit and academic groups.

For further information, visit www.optibrium.com.